-
公开(公告)号：US08414896B2
公开(公告)日：2013-04-09
申请号：US12945527
申请日：2010-11-12
申请人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
发明人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C07K14/71
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
公开(公告)号：US20110135636A1
公开(公告)日：2011-06-09
申请号：US12945527
申请日：2010-11-12
申请人： Mikkel Wandahl PEDERSEN , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
发明人： Mikkel Wandahl PEDERSEN , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
公开(公告)号：US20110129855A1
公开(公告)日：2011-06-02
申请号：US12945495
申请日：2010-11-12
申请人： MIKKEL WANDAHL PEDERSEN , LUCILLA STEINAA , ALLAN JENSEN , KLAUS KOEFOED , PER-JOHAN MEIJER , ROBERT CARLSSON , CHARLES PYKE , LARS SOGAARD NIELSEN
发明人： MIKKEL WANDAHL PEDERSEN , LUCILLA STEINAA , ALLAN JENSEN , KLAUS KOEFOED , PER-JOHAN MEIJER , ROBERT CARLSSON , CHARLES PYKE , LARS SOGAARD NIELSEN
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
-
公开(公告)号：US20090004192A1
公开(公告)日：2009-01-01
申请号：US12074056
申请日：2008-02-29
申请人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meuer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
发明人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meuer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
IPC分类号： A61K39/395 , G01N33/566 , C12N15/12 , C07K14/47 , C07K16/22 , C12N15/85 , A61P35/00 , C12P21/02 , C12N5/16 , C12N5/10
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
-
-
搜索结果
4 条记录 (耗时 0.025 秒)
